IP Library › Granted Patent US 12,466,790
Granted Patent B1
US 12,466,790 · App. 18/957,414 · Granted Nov 11, 2025

Bis urea-based organoselenium compound and method for treating cancer

Inventors: Tarek Ahmed Yousef (Riyadh, SA); Saad Shaaban (Almansourah, EG); Ahmed A. Al-Karmalawy (Baghdad, IQ); Marwa Sharaky (Cairo, EG); Hussein Ba-Ghazal (Riyadh, SA); Mohamed Alaasar (Halle Saale, DE)
Assignee: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
C07C391/02A61K31/17A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,790
App. No.
18/957,414
Granted
Nov 11, 2025
Kind
B1
Abstract

A method of treating cancer including administering a bis-(organoselanyl urea)aryl agent having a Formula (I) to a subject with cancer. The method includes effective inhibition of growth of cancer cells using the compound of Formula (I) as compared to doxorubicin.

Claims (18)

1 . A method for inhibiting in vitro growth of a cancer cell of a cancer cell line selected from the group consisting of HN9, HuH7, FaDu, MCF7, HEPG2, A549, HCT116, and A375, comprising:

contacting the cancer cell with a bis-(organoselanyl urea)aryl agent of formula (I):

wherein R 1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl.

2 . The method of claim 1 , wherein the contacting of the bis-(organoselanyl urea)aryl agent provides a cancer cell growth inhibition percentage of at least 5%.

3 . The method of claim 1 , wherein the cell line is the HN9.

4 . The method of claim 1 , wherein the contacting of the cancer cell with the bis-(organoselanyl urea)aryl agent provides a cancer cell growth inhibition percentage of at least 5% against HCT116.

5 . The method of claim 1 , wherein the contacting of the cancer cell with the bis-(organoselanyl urea)aryl agent provides a cancer cell growth inhibition percentage of at least 9% against HN9.

6 . The method of claim 1 , wherein the cell line is HuH7.

7 . The method of claim 1 , wherein the cell line is FaDu.

8 . The method of claim 1 , wherein the cell line is MCF7.

9 . The method of claim 1 , wherein the cell line is HEPG2.

10 . The method of claim 1 , wherein the cell line is A549.

11 . The method of claim 1 , wherein the cell line is HCT116.

12 . The method of claim 1 , wherein the cell line is A375.

13 . The method of claim 1 , wherein R 1 in the bis-(organoselanyl urea)aryl agent of formula (I) is methyl.

14 . The method of claim 1 , wherein R 1 in the bis-(organoselanyl urea)aryl agent of formula (I) is ethyl.

15 . The method of claim 1 , wherein R 1 in the bis-(organoselanyl urea)aryl agent of formula (I) is n-propyl.

16 . The method of claim 1 , wherein R 1 in the bis-(organoselanyl urea)aryl agent of formula (I) is isopropyl.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE FIRST INVENTOR'S EXECUTION DATE PREVIOUSLY RECORDED AT REEL: 70259 FRAME: 12. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 7, 2025
From: YOUSEF, TAREK AHMED; SHAABAN, SAAD; AL-KARMALAWY, AHMED A.; SHARAKY, MARWA; BA-GHAZAL, HUSSEIN; ALAASAR, MOHAMED
To: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
Reel/Frame 070439/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2025
From: YOUSEF, TAREK AHMED; SHAABAN, SAAD; AL-KARMALAWY, AHMED A.; SHARAKY, MARWA; BA-GHAZAL, HUSSEIN; ALAASAR, MOHAMED
To: IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY
Reel/Frame 070259/0012 →
References Cited (9)
US 11970464B1 · Shaaban et al. · 2024 [cited by applicant]
US 11999708B1 · Shaaban et al. · 2024 [cited by applicant]
WO 2004047925A2 · 2004 [cited by applicant]
Altea-Manzano et al. (EMBO Reports (2020) 21: e50635. DOI 10.15252/embr.202050635). (Year: 2020). [cited by examiner]
Chalak et al. (Life (2024), 14, 417. https://doi.org/10.3390/life14030417). (Year: 2024). [cited by examiner]
Tang et al. (Front. Pharmacol. (2024), 15:1466017. doi: 10.3389/fphar.2024.1466017). (Year: 2024). [cited by examiner]
Antunes et al. (Bioengineering (2022), 9, 166). (Year: 2022). [cited by examiner]
Fardous F El-Senduny, et al., “Urea-functionalized Organoselenium Compounds as Promising anti-HepG2 and Apoptosis-inducing Agents”, Future Medicinal Chemistry, vol. 13, Issue 19, Aug. 24, 2021, pp. 1655-1677, 5 Pages. [cited by applicant]
Yousong Nie, et al.; “New Organoselenium (NSAIDs-Selenourea and Isoselenocyanate) Derivatives as Potential. Antiproliferative Agents: Synthesis, Biological Evaluation and in Silico Calculations”, Molecules, vol. 27, Iss… [cited by applicant]